Abstract

BackgroundIn recent years, the concept of liquid biopsy diagnostics in detection and progress monitoring of malignant diseases gained significant awareness. We here report on a semi-quantitative real-time cytokeratin 20 RT-PCR-based assay, for detecting circulating tumor cells within a fraction of peripheral blood mononuclear cells in colorectal cancer patients.MethodsIn total, 381 patients were included. Prior to surgical tumor resection, a peripheral blood sample was drawn. Mononuclear cells were isolated by Ficoll centrifugation and a cytokeratin 20 qRT-PCR assay was performed. Quantitative PCR data was assessed regarding histopathological characteristics and patients´ clinical outcome.ResultsA cut-off value was determined at ≥ 2.77 [EU]. Stratifying patients by this cut-off, it represents a statistically highly significant prognostic marker for both the overall and disease-free survival in the entire cohort UICC I-IV (both p<0.001) and in early tumor stages UICC I+II (overall survival p=0.003 and disease-free survival p=0.005). In multivariate analysis, the cut-off value stands for an independent predictor of significantly worse overall and disease-free survival (p=0.035 and p=0.047, respectively).ConclusionWe successfully established a highly sensitive real-time qRT-PCR assay by which we are able to identify colorectal cancer patients at risk for an unfavorable prognosis in UICC I and II stages.

Highlights

  • Colorectal cancer (CRC) still counts for the second most frequent cause of cancer death [1]

  • We report on a refined quantitative real-time cytokeratin 20 (CK20) RT-polymerase chain reaction (PCR), that bears the possibility to semi-quantitatively analyze the circulating tumor cells (CTC)/peripheral blood mononuclear cells (PBMC) fraction in the peripheral blood

  • The study cohort consisted of 381 patients, all diagnosed with histologically confirmed colorectal cancer

Read more

Summary

Introduction

Colorectal cancer (CRC) still counts for the second most frequent cause of cancer death [1]. In patients with UICC (Union internationale contre le cancer) stage III and IV CRC, a significant increase in survival could be achieved in recent decades, primarily owed to new therapeutic regimes including antibody-based immunotherapies [2, 3]. This progress though was not fully transferred to patients with early stage CRC [4]. We here report on a semi-quantitative real-time cytokeratin 20 RT-PCR-based assay, for detecting circulating tumor cells within a fraction of peripheral blood mononuclear cells in colorectal cancer patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call